<aBoston's Q2 reveals that the startup rebound isn't ahead of us, it's upon us

<aBoston's Q2 reveals that the startup rebound isn't ahead of us, it's upon us

The coronavirus caused some argument amongst Boston’s equity capital neighborhood. Looking back at our mid-2020 study of its VCs, some saw the city’s strength in biotech and health care as a competitive benefit, while others saw Boston’s diverse start-up environment as crucial to its survival. And some were fretted that activity was about to clamp down. […]
, some saw the city’s strength in biotech and health care as a competitive advantage, while others saw Boston’s diverse start-up community as key to its survival. With fresh information in hand, it appears that the more bullish were more right than the bears and that, in an excellent turn of affairs for Boston startups, Bussgang was incorrect. …